Genetics of valvular heart disease

Current Cardiology Reports

Volumn 16, Issue 6, 2014, Pages

  LaHaye, Stephanie ^a,b   Lincoln, Joy ^a,b   Garg, Vidu ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Aortic valve calcification; Aortic valve stenosis; Bicuspid aortic valve; Ebstein anomaly; Genetics; Heartvalve; Heartvalvedevelopment; Mitral valve prolapse; Myxomatous valve disease; Pulmonic valve stenosis; Valvular heart disease

Indexed keywords

ACTIVIN RECEPTOR 1; AGGRECANASE 2; COLLAGEN TYPE 1; COLLAGEN TYPE 11; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 5; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRILLIN 1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; NOTCH1 RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMAD2 PROTEIN; SMAD6 PROTEIN; SOS PROTEIN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; ANTICOAGULANT AGENT;

ADAMTS5 GENE; ALK2 GENE; BICUSPID AORTIC VALVE; COLLAGEN TYPE 1 GENE; COLLAGEN TYPE 2 GENE; COLLAGEN TYPE 3 GENE; COLVA1 GENE; COLXA1 GENE; FBN1 GENE; FLNA GENE; GATA4 GENE; GATA5 GENE; GENE; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; KCNJ2 GENE; MITRAL VALVE PROLAPSE; MYH7 GENE; NONHUMAN; NOS3 GENE; NOTCH1 GENE; ONCOGENE K RAS; PROTEIN PHOSPHORYLATION; PTPN11 GENE; PULMONARY VALVE DISEASE; RAF1 GENE; REVIEW; SIGNAL TRANSDUCTION; SMAD2 GENE; SMAD6 GENE; SOS1 GENE; TGFBR1 GENE; TGFBR2 GENE; TRICUSPID VALVE DISEASE; VALVULAR HEART DISEASE; ABNORMALITIES; ADULT; AORTA VALVE; CHILD; EBSTEIN ANOMALY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HEART ASSIST DEVICE; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; LIFE EXPECTANCY; PREVALENCE; PULMONARY VALVE STENOSIS; TRENDS; UTILIZATION;

ADULT; ANTICOAGULANTS; AORTIC VALVE; CHILD; EBSTEIN ANOMALY; GENOME-WIDE ASSOCIATION STUDY; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HEART-ASSIST DEVICES; HUMANS; LIFE EXPECTANCY; MITRAL VALVE PROLAPSE; PREVALENCE; PULMONARY VALVE STENOSIS;

EID: 84901336620     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0487-2     Document Type: Review

References (99)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. Hoffman JI, Kaplan S. The incidence of congenital heart disease. JACC. 2002;12:1890-900. (Pubitemid 34628268)
3. Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular heart disease: diagnosis and management. Mayo Clin Proc. 2010;85:483-500.
4. Garg V. Growth of the normal human heart. In: Preedy VR, editor. Handbook of growth and growth monitoring in health and disease. New York: Springer; 2011.
5. Garg V. Molecular basis of cardiac development and congenital heart disease. In: Patterson C, Willis M, editors. Translational Cardiology. New York: Humana Press; 2012.
6. Garg V. Insights into the genetic basis of congenital heart disease. Cell Mol Life Sci. 2006;63:1141-8. (Pubitemid 43939001)
7. Combs MD, Yutzey KE. Heart valve development: regulatory networks in development and disease. Circ Res. 2009;105:408-21.
8. Fishman MC, Chien KR. Fashioning the vertebrate heart: earliest embryonic decisions. Development. 1997;124:2099-117. (Pubitemid 27283233)
9. Brown CB, Boyer AS, Runyan RB, Barnett JV. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science. 1999;283:2080-2.
10. Nakajima Y, Yamagishi T, Hokari S, Nakamura H. Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec. 2000;258:119-27. (Pubitemid 30082904)
11. Sugi Y, Yamamura H, Okagawa H, Markwald RR. Bone morphogenetic protein-2 can mediatemyocardial regulation of atrioventricular cushion mesenchymal cell formation in mice. Dev Biol. 2004;269:505-18. (Pubitemid 38521114)
12. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99-115. (Pubitemid 38090691)
13. Yutzey KE, Colbert M, Robbins J. Ras-related signaling pathways in valve development: ebb and flow. Physiology. 2005;20:390-7. (Pubitemid 41812422)
14. Wessels A, van den Hoff MJ, Adamo RF, Phelps AL, Lockhart MM, Sauls K, et al. Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. Dev Biol. 2012;366:111-24.
15. Gittenberger-de Groot AC, Vrancken Peeters MP, Mentink MM, Gourdie RG, Poelmann RE. Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. Circ Res. 1998;82:1043-52. (Pubitemid 28253329)
16. Briggs LE, Phelps AL, Brown E, Kakarla J, Anderson RH, van den Hoff MJ, et al. Expression of the BMP receptor Alk3 in the second heart field is essential for development of the dorsal mesenchyme protrusion and atrioventricular septation. Circ Res. 2013;112:1420-32.
17. Chang CP, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, et al. A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell. 2004;118:649-63. (Pubitemid 39179716)
18. Wu B, Wang Y, Lui W, Langworthy M, Tompkins KL, Hatzopoulos AK, et al. Nfatc1 coordinates valve endocardial cell lineage development required for heart valve formation. Circ Res. 2011;109:183-92.
19. Wirrig EE, Yutzey KE. Transcriptional regulation of heart valve development and disease. Cardiovas Pathol. 2011;20:162-7.
20. Hinton RB, Yutzey KE. Heart valve structure and function in development and disease. Annu Rev Physiol. 2011;73:29-46.
21. Hinton RB, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, et al. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res. 2006;98:1431-8. (Pubitemid 43948068)
22. Ward C. Clinical significance of the bicuspid aortic valve. Heart. 2000;83:81-5. (Pubitemid 30307645)
23. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-4. (Pubitemid 41294491)
24. Vallely MP, Semsarian C, Bannon PG. Management of the ascending aorta in patients with bicuspid aortic valve disease. Heart Lung Circ. 2008;17:357-63.
25. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55:2789-800.
26. Fedak PW, Verma S, David TE, Leask RL, Weisel RD, Butany J. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation. 2002;106:900-4. (Pubitemid 34925320)
27. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol. 2004;44: 138-43. (Pubitemid 38968472)
28. McBride KL, Garg V. Heredity of bicuspid aortic valve: is family screening indicated? Heart. 2011;97:1193-5.
29. de la Pompa JL, Epstein JA. Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev Cell. 2012;22:244-54.
30. High FA, Epstein JA. The multifaceted role of Notch in cardiac development and disease. Nat Rev Genet. 2008;9:49-61.
31. Foffa I, Ait Ali L, Panesi P, Mariani M, Festa P, Botto N, et al. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. BMC Med Genet. 2013;14:44.
32. McKellar SH, Tester DJ, Yagubyan M, Majumdar R, Ackerman MJ, Sundt TM. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007;134:290-6. (Pubitemid 47088578)
33. Mohamed SA, Aherrahrou Z, Liptau H, Erasmi AW, Hagemann C, Wrobel S, et al. Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun. 2006;345:1460-5. (Pubitemid 43817895)
34. Laforest B, Andelfinger G, Nemer M. Loss of Gata5 in mice leads to bicuspid aortic valve. J Clin Invest. 2011;121:2876-87.
35. • Padang R, Bagnall RD, Richmond DR, Bannon PG, Semsarian C. Rare non-synonymous variations in the transcriptional activation domains of GATA5 in bicuspid aortic valve disease. J Mol Cell Cardiol. 2012;53:277-81. This study is the first to identify rare sequence variants in the gene, GATA5, in humans with BAV.
36. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet. 2000;24:171-4. (Pubitemid 30094719)
37. • Tan HL, Glen E, Topf A, Hall D, O'Sullivan JJ, Sneddon L, et al. Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation. Hum Mutat. 2012;33:720-7. This study is the first to report an association between rare sequence variants with functional deficits in the gene, SMAD6, in humans with bicuspid aortic valve.
38. Sans-Coma V, Cardo M, Thiene G, Fernandez B, Arque JM, Duran AC. Bicuspid aortic and pulmonary valves in the Syrian hamster. Int J Cardiol. 1992;34:249-54.
39. Sans-Coma V, Carmen Fernandez M, Fernandez B, Duran AC, Anderson RH, Arque JM. Genetically alike Syrian hamsters display both bifoliate and trifoliate aortic valves. J Anat. 2012;220:92-101.
40. Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation. 2000;101:2345-8. (Pubitemid 30329122)
41. • Bosse K, Hans CP, Zhao N, Koenig SN, Huang N, Guggilam A, et al. Endothelial nitric oxide signaling regulates NOTCH1 in aortic valve disease. J Mol Cell Cardiol. 2013;60:27-35. The authors describe the first highly penetrant mouse model for bicuspid aortic valve by generating mice, which are haploinsufficient for NOTCH1 in a endothelial nitric oxide synthase (Nos3)-null background.
42. Dupuis LE, Osinska H, Weinstein MB, Hinton RB, Kern CB. Insufficient versican cleavage and Smad2 phosphorylation results in bicuspid aortic and pulmonary valves. J Mol Cell Cardiol. 2013;60:50-9.
43. Thomas PS, Sridurongrit S, Ruiz-Lozano P, Kaartinen V. Deficient signaling via Alk2 (Acvr1) leads to bicuspid aortic valve development. PloS ONE. 2012;7:e35539.
44. Kolibash AJ, Kilman JW, Bush CA, Ryan JM, Fontana ME, Wooley CF. Evidence for progression from mild to severe mitral regurgitation in mitral valve prolapse. Am J Cardiol. 1986;58:762-7. (Pubitemid 17004240)
45. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341:1-7. (Pubitemid 29293713)
46. Baddour LM, Bisno AL. Mitral valve prolapse: multifactorial etiologies and variable prognosis. Am Heart J. 1986;112:1359-62.
47. Baddour LM, Phillips TN, Bisno AL. Coagulase-negative staphylococcal endocarditis. Occurrence in patients with mitral valve prolapse. Arch Intern Med. 1986;146:119-21. (Pubitemid 16158639)
48. Levine RA, Slaugenhaupt SA. Molecular genetics of mitral valve prolapse. Curr Opin Cardiol. 2007;22:171-5. (Pubitemid 46584579)
49. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001;104:2525-32. (Pubitemid 33104788)
50. Gupta V, Barzilla JE, Mendez JS, Stephens EH, Lee EL, Collard CD, et al. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol. 2009;18:191-7.
51. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1994;352:337-9.
52. Maslen CL, Corson GM, Maddox BK, Glanville RW, Sakai LY. Partial sequence of a candidate gene for the Marfan syndrome. Nature. 1991;352:334-7. (Pubitemid 21912352)
53. Lee B, Godfrey M, Vitale E, Hori H, Mattei MG, Sarfarazi M, et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991;352:330-4. (Pubitemid 21912351)
54. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407-11. (Pubitemid 36278859)
55. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in amousemodel of Marfan syndrome. J Clin Invest. 2004;114:1586-92. (Pubitemid 40385549)
56. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-21.
57. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37:275-81. (Pubitemid 41716254)
58. Liberfarb RM, Goldblatt A. Prevalence of mitral-valve prolapse in the Stickler syndrome. Am J Med Genet. 1986;24:387-92. (Pubitemid 16017633)
59. Najib MQ, Schaff HV, Ganji J, Lee HR, Click RL, Miller DC, et al. Valvular heart disease in patients with osteogenesis imperfecta. J Card Surg. 2013;28:139-43.
60. Malfait F, Wenstrup RJ, De Paepe A. Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. Genet Med. 2010;12:597-605.
61. Lincoln J, Lange AW, Yutzey KE. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol. 2006;294:292-302. (Pubitemid 43884820)
62. Ritelli M, Dordoni C, Venturini M, Chiarelli N, Quinzani S, Traversa M, et al. Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations. Orphanet J Rare. 2013;8:58.
63. Lincoln J, Florer JB, Deutsch GH, Wenstrup RJ, Yutzey KE. ColVa1 and ColXIa1 are required for myocardial morphogenesis and heart valve development. Dev Dyn. 2006;235:3295-305. (Pubitemid 44888195)
64. Henney AM, Tsipouras P, Schwartz RC, Child AH, Devereux RB, Leech GJ. Genetic evidence that mutations in the COL1A1, COL1A2, COL3A1, or COL5A2 collagen genes are not responsible for mitral valve prolapse. Br Heart J. 1989;61:292-9. (Pubitemid 19088479)
65. Wordsworth P, Ogilvie D, Akhras F, Jackson G, Sykes B. Genetic segregation analysis of familial mitral valve prolapse shows no linkage to fibrillar collagen genes. Br Heart J. 1989;61:300-6. (Pubitemid 19088480)
66. Disse S, Abergel E, Berrebi A, Houot AM, Le Heuzey JY, Diebold B, et al. Mapping of a first locus for autosomal dominant myxomatous mitral-valve prolapse to chromosome 16p11.2-p12.1. Am J Hum Genet. 1999;65:1242-51. (Pubitemid 30460374)
67. Lardeux A, Kyndt F, Lecointe S, Marec HL, Merot J, Schott JJ, et al. Filamin-a-related myxomatous mitral valve dystrophy: genetic, echocardiographic and functional aspects. J Cardiovasc Transl Res. 2011;4:748-56.
68. Kyndt F, Gueffet JP, Probst V, Jaafar P, Legendre A, Le Bouffant F, et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation. 2007;115:40-9. (Pubitemid 46058610)
69. • Sauls K, de Vlaming A, Harris BS, Williams K, Wessels A, Levine RA, et al. Developmental basis for filamin-A-associated myxomatous mitral valve disease. Cardiovasc Res. 2012;96:109-19. The authors describe the first mouse model of myxomatous mitral valve disease associated with mutation of Filamin A.
70. Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K. Filamin associates with Smads and regulates transforming growth factor-beta signaling. J Biol Chem. 2001;276:17871-7.
71. Feng Y, Chen MH, Moskowitz IP, Mendonza AM, Vidali L, Nakamura F, et al. Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac morphogenesis. Proc Natl Acad Sci U S A. 2006;103:19836-41. (Pubitemid 46037517)
72. Hart AW, Morgan JE, Schneider J, West K, McKie L, Bhattacharya S, et al. Cardiac malformations and midline skeletal defects in mice lacking filamin A. Hum Mol Genet. 2006;15:2457-67. (Pubitemid 44288699)
73. Kern CB, Wessels A, McGarity J, Dixon LJ, Alston E, Argraves WS, et al. Reduced versican cleavage due to Adamts9 haploinsufficiency is associated with cardiac and aortic anomalies. Matrix Biol. 2010;29:304-16.
74. Mahimkar R, Nguyen A, Mann M, Yeh CC, Zhu BQ, Karliner JS, et al. Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol. 2009;18:253-61.
75. Barnette DN, Hulin A, Ahmed AS, Colige AC, Azhar M, Lincoln J. Tgfbeta-Smad and MAPK signaling mediate scleraxis and proteoglycan expression in heart valves. J Mol Cell Cardiol. 2013;65:137146.
76. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-900. (Pubitemid 34628268)
77. Hatemi AC, Gursoy M, Tongut A, Bicakhan B, Guzeltas A, Cetin G, et al. Pulmonary stenosis as a predisposing factor for infective endocarditis in a patient with Noonan syndrome. Tex Heart Inst J. 2010;37:99-101.
78. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet. 2005;6:45-68. (Pubitemid 41397075)
79. Sznajer Y, Keren B, Baumann C, Pereira S, Alberti C, Elion J, et al. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics. 2007;119:e1325-31. (Pubitemid 46871252)
80. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med. 2004;10: 849-57. (Pubitemid 39070859)
81. Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A. 2009;106:4736-41.
82. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/ MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29:992-1006.
83. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev. 2007;17:15-22. (Pubitemid 46109294)
84. Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. 2011;25:161-79.
85. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 2003;424:443-7. (Pubitemid 36917494)
86. Okubo A, Miyoshi O, Baba K, Takagi M, Tsukamoto K, Kinoshita A, et al. A novel GATA4 mutation completely segregated with atrial septal defect in a large Japanese family. J Med Genet. 2004;41:e97.
87. Xiang R, Fan LL, Huang H, Cao BB, Li XP, Peng DQ, et al. A novel mutation of GATA4 (K319E) is responsible for familial atrial septal defect and pulmonary valve stenosis. Gene. 2014;534:320-3.
88. Misra C, Sachan N, McNally CR, Koenig SN, Nichols HA, Guggilam A, et al. Congenital heart disease-causing Gata4 mutation displays functional deficits in vivo. PLoS Genet. 2012;8:e1002690.
89. Maragh S, Miller RA, Bessling SL, McGaughey DM, Wessels MW, de Graaf B, et al. Identification of RNA binding motif proteins essential for cardiovascular development. BMC Dev Biol. 2011;11:62.
90. • Postma AV, van Engelen K, van deMeerakker J, Rahman T, Probst S, Baars MJ, et al. Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ Cardiovasc Genet. 2011;4:43-50. This study is the first to report mutations in MYH7 in individuals with Ebstein anomaly of the tricuspid valve.
91. Bettinelli AL, Mulder TJ, Funke BH, Lafferty KA, Longo SA, Niyazov DM. Familial Ebstein anomaly, left ventricular hypertrabeculation, and ventricular septal defect associated with a MYH7 mutation. Am J Med Genet A. 2013;161:3187-90.
92. Horne BD, Camp NJ, Muhlestein JB, Cannon-Albright LA. Evidence for a heritable component in death resulting from aortic and mitral valve diseases. Circulation. 2004;110:3143-8. (Pubitemid 39492011)
93. Lewin MB, Otto CM. The bicuspid aortic valve: adverse outcomes from infancy to old age. Circulation. 2005;111:832-4. (Pubitemid 40279882)
94. Nigam V, Srivastava D. NOTCH1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol. 2009;47:828-34.
95. Lincoln J, Kist R, Scherer G, Yutzey KE. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol. 2007;305:120-32. (Pubitemid 46613795)
96. Acharya A, Hans CP, Koenig SN, Nichols HA, Galindo CL, Garner HR, et al. Inhibitory role of NOTCH1 in calcific aortic valve disease. PloS ONE. 2011;6:e27743.
97. Probst V, Le Scouarnec S, Legendre A, Jousseaume V, Jaafar P, Nguyen JM, et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation. 2006;113:856-60.
98. Bella JN, Tang W, Kraja A, Rao DC, Hunt SC, Miller MB, et al. Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study. Hypertension. 2007;49:453-60.
99. •• Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-12. First largescale genome-wide association study linking genetic variation in LPA (which encodes for lipoprotein A) locus with aortic valve calcification and aortic stenosis.